LANCL2

Summary

LANCL2 (LanC like glutathione S-transferase 2, HGNC:6509) is a protein-coding gene on chromosome 7p11.2, encoding LanC-like protein 2 (Q9NS86). Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.

Enables phosphatidylinositol-3-phosphate binding activity; phosphatidylinositol-4-phosphate binding activity; and phosphatidylinositol-5-phosphate binding activity. Involved in negative regulation of DNA-templated transcription and positive regulation of abscisic acid-activated signaling pathway. Located in several cellular components, including cortical actin cytoskeleton; cytosol; and nucleoplasm.

Source: NCBI Gene 55915 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 83 total
• GTEx eGene: eQTL in 28 tissues, sQTL in 1 (q < 0.05)
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.85 (unconstrained)
• MANE Select transcript: NM_018697
• Notable: 83 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6509
Approved symbol	LANCL2
Name	LanC like glutathione S-transferase 2
Location	7p11.2
Locus type	gene with protein product
Status	Approved
Aliases	TASP
Ensembl gene	ENSG00000132434
Ensembl biotype	protein_coding
OMIM	612919
Entrez	55915

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 8 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 1 retained_intron

MANE Select: ENST00000254770

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 4: 1, TSL 5: 2

ENST00000254770, ENST00000452107, ENST00000466041, ENST00000476479, ENST00000486376, ENST00000872235, ENST00000872236, ENST00000916639, ENST00000952390, ENST00000952391, ENST00000993513, ENST00001048663, ENST00001107803, ENST00001136432

RefSeq mRNA: 1 — MANE Select: NM_018697 NM_018697

CCDS: CCDS5517

Canonical transcript exons

ENST00000254770 — 9 exons

Exon	Start	End
ENSE00001175819	55431226	55433737
ENSE00001243070	55365337	55366229
ENSE00003476274	55428375	55428447
ENSE00003485538	55391793	55391910
ENSE00003530655	55401174	55401320
ENSE00003586545	55425254	55425430
ENSE00003589486	55398423	55398630
ENSE00003666733	55399957	55400104
ENSE00003692203	55411907	55412089

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 93.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.6456 / max 100.4753, expressed in 1810 samples.

Highest expression (Bgee): middle temporal gyrus, lateral nuclear group of thalamus, primordial germ cell in gonad, entorhinal cortex, postcentral gyrus.

Genetic regulation across tissues (GTEx eQTL / sQTL)

LANCL2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 28 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 29 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Thyroid	eqtl	2.4e-07	-0.18	7:55365571:C:A
Artery Aorta	eqtl	2.7e-06	+0.16	7:55473014:G:A
Brain Cerebellum	eqtl	8.1e-06	-0.31	7:55356109:C:T
Cells Cultured fibroblasts	eqtl	1.3e-05	+0.15	7:55305495:A:G
Brain Nucleus accumbens basal ganglia	eqtl	4.5e-05	+0.25	7:55439887:A:G
Adipose Subcutaneous	eqtl	9.5e-05	-0.12	7:55161850:T:C
Skin Sun Exposed Lower leg	eqtl	2.8e-04	+0.10	7:55352829:G:A
Muscle Skeletal	eqtl	3.2e-04	+0.11	7:55409143:C:T
Testis	sqtl	4.9e-04	-0.39	7:55375684:G:A
Cells EBV-transformed lymphocytes	eqtl	5.6e-04	+0.16	7:55473014:G:A
Brain Caudate basal ganglia	eqtl	8.3e-04	+0.24	7:55334339:G:A
Whole Blood	eqtl	1.5e-03	+0.12	7:55484139:T:C
Brain Spinal cord cervical c-1	eqtl	2.8e-03	-0.27	7:55396248:GGTCTTCATGGTGAGTATCAGAGACAACTCCC:G
Spleen	eqtl	2.8e-03	+0.20	7:55473014:G:A
Colon Transverse	eqtl	3.4e-03	+0.09	7:55446094:T:G
Breast Mammary Tissue	eqtl	4.1e-03	+0.10	7:54546892:A:G
Brain Cortex	eqtl	4.5e-03	+0.20	7:55357447:C:T
Brain Anterior cingulate cortex BA24	eqtl	5.0e-03	+0.23	7:55344968:G:GCGCCCGCCCGCCTCTCCTGC
Brain Cerebellar Hemisphere	eqtl	5.6e-03	-0.23	7:55342121:T:C
Colon Sigmoid	eqtl	6.8e-03	-0.10	7:55238273:C:T

FANTOM5 promoters

showing 10 of 12 alternative TSS:

Promoter ID	TPM avg	Samples expressed
78734	8.5546	1796
78728	2.8328	972
78735	2.5436	1102
78731	0.1973	116
78727	0.1215	48
78729	0.1166	59
78732	0.0971	39
78730	0.0842	35
78739	0.0514	18
78736	0.0234	1

Top tissues by expression

showing 100 of 282 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	93.96	gold quality
lateral nuclear group of thalamus	UBERON:0002736	92.74	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.86	gold quality
entorhinal cortex	UBERON:0002728	91.67	gold quality
postcentral gyrus	UBERON:0002581	91.32	gold quality
parietal lobe	UBERON:0001872	91.21	gold quality
superior frontal gyrus	UBERON:0002661	90.67	gold quality
prefrontal cortex	UBERON:0000451	90.22	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.18	gold quality
sperm	CL:0000019	90.16	gold quality
endothelial cell	CL:0000115	89.50	gold quality
temporal lobe	UBERON:0001871	89.46	gold quality
frontal cortex	UBERON:0001870	88.85	gold quality
neocortex	UBERON:0001950	88.50	gold quality
cerebral cortex	UBERON:0000956	88.29	gold quality
pons	UBERON:0000988	88.29	gold quality
lateral globus pallidus	UBERON:0002476	88.27	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.21	gold quality
Ammon’s horn	UBERON:0001954	88.08	gold quality
superior vestibular nucleus	UBERON:0007227	88.08	gold quality
anterior cingulate cortex	UBERON:0009835	88.01	gold quality
subthalamic nucleus	UBERON:0001906	87.93	gold quality
cingulate cortex	UBERON:0003027	87.87	gold quality
telencephalon	UBERON:0001893	87.84	gold quality
male germ cell	CL:0000015	87.78	gold quality
primary visual cortex	UBERON:0002436	87.77	gold quality
amygdala	UBERON:0001876	87.65	gold quality
corpus callosum	UBERON:0002336	87.51	gold quality
left testis	UBERON:0004533	87.41	gold quality
occipital lobe	UBERON:0002021	87.28	gold quality
nucleus accumbens	UBERON:0001882	87.23	gold quality
inferior vagus X ganglion	UBERON:0005363	87.20	gold quality
right frontal lobe	UBERON:0002810	87.16	gold quality
testis	UBERON:0000473	87.11	gold quality
right testis	UBERON:0004534	87.03	gold quality
cortical plate	UBERON:0005343	86.87	gold quality
ventral tegmental area	UBERON:0002691	86.75	gold quality
forebrain	UBERON:0001890	86.68	gold quality
caudate nucleus	UBERON:0001873	86.56	gold quality
dorsal plus ventral thalamus	UBERON:0001897	86.55	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.37	gold quality
medial globus pallidus	UBERON:0002477	86.28	gold quality
globus pallidus	UBERON:0001875	86.22	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.17	gold quality
brain	UBERON:0000955	85.72	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	85.55	gold quality
putamen	UBERON:0001874	85.45	gold quality
spinal cord	UBERON:0002240	85.17	gold quality
substantia nigra pars reticulata	UBERON:0001966	84.67	gold quality
substantia nigra pars compacta	UBERON:0001965	84.30	gold quality
left ovary	UBERON:0002119	84.23	gold quality
stromal cell of endometrium	CL:0002255	84.19	gold quality
ovary	UBERON:0000992	83.49	gold quality
medulla oblongata	UBERON:0001896	83.48	gold quality
adult organism	UBERON:0007023	83.43	gold quality
rectum	UBERON:0001052	83.33	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	83.19	silver quality
right adrenal gland cortex	UBERON:0035827	82.98	gold quality
hypothalamus	UBERON:0001898	82.84	gold quality
right adrenal gland	UBERON:0001233	82.81	gold quality
cerebellar vermis	UBERON:0004720	82.65	gold quality
left adrenal gland	UBERON:0001234	82.42	gold quality
cerebellar cortex	UBERON:0002129	82.28	gold quality
cerebellar hemisphere	UBERON:0002245	82.20	gold quality
cerebellum	UBERON:0002037	82.05	gold quality
right ovary	UBERON:0002118	82.00	gold quality
body of uterus	UBERON:0009853	81.89	gold quality
adrenal tissue	UBERON:0018303	81.88	gold quality
right hemisphere of cerebellum	UBERON:0014890	81.83	gold quality
gingival epithelium	UBERON:0001949	81.75	gold quality
adrenal gland	UBERON:0002369	81.57	gold quality
endometrium	UBERON:0001295	81.48	gold quality
adrenal cortex	UBERON:0001235	81.39	gold quality
left adrenal gland cortex	UBERON:0035825	81.38	gold quality
midbrain	UBERON:0001891	81.33	gold quality
hindlimb stylopod muscle	UBERON:0004252	81.20	gold quality
mucosa of transverse colon	UBERON:0004991	81.15	gold quality
ventricular zone	UBERON:0003053	81.13	gold quality
ganglionic eminence	UBERON:0004023	80.97	gold quality
muscle of leg	UBERON:0001383	80.89	gold quality
gastrocnemius	UBERON:0001388	80.79	gold quality
substantia nigra	UBERON:0002038	80.64	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.60	gold quality
skin of hip	UBERON:0001554	80.54	gold quality
female reproductive system	UBERON:0000474	80.45	gold quality
upper leg skin	UBERON:0004262	80.45	gold quality
placenta	UBERON:0001987	80.40	gold quality
adult mammalian kidney	UBERON:0000082	80.38	gold quality
uterus	UBERON:0000995	80.24	gold quality
islet of Langerhans	UBERON:0000006	80.22	gold quality
skin of leg	UBERON:0001511	80.20	gold quality
gingiva	UBERON:0001828	80.14	gold quality
duodenum	UBERON:0002114	80.11	gold quality
ileal mucosa	UBERON:0000331	80.07	gold quality
smooth muscle tissue	UBERON:0001135	80.06	gold quality
endocervix	UBERON:0000458	79.98	gold quality
skin of abdomen	UBERON:0001416	79.95	gold quality
corpus epididymis	UBERON:0004359	79.89	gold quality
right lobe of thyroid gland	UBERON:0001119	79.84	gold quality
jejunum	UBERON:0002115	79.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.41

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 78 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Frontal cortex	tissue	60.7
Cerebral cortex	tissue	43.0	high
Somatosensory cortex	tissue	43.0
Cerebellum	tissue	41.2	low
Motor cortex	tissue	38.4
Occipital cortex	tissue	38.4
Prefrontal cortex	tissue	37.1
Hippocampal formation	tissue	36.9
Entorhinal cortex	tissue	36.9
Temporal cortex	tissue	36.2
Retrosplenial and cingulate cortex	tissue	35.0
Insular cortex	tissue	34.7
Retrosplenial cortex	tissue	34.3
Amygdala	tissue	32.0
Thalamus	tissue	31.2
Pons	tissue	30.2
Superior colliculi	tissue	28.8
Midbrain	tissue	28.5
Olfactory bulb	tissue	27.1
Postcentral gyrus	tissue	27.0
Hippocampus	tissue	26.1	medium
Hypothalamus	tissue	25.3
Caudate putamen	tissue	25.3
Substantia nigra	tissue	24.9
Ventral forebrain	tissue	24.8
Septum	tissue	24.7
Basal ganglia	tissue	24.2	not detected
Putamen	tissue	23.8
Medulla oblongata	tissue	23.8
Nucleus accumbens	tissue	22.2
Spinal cord	tissue	22.0
Periaqueductal gray	tissue	22.0
Corpus callosum	tissue	20.5
Locus coeruleus	tissue	16.3
Ovary	tissue	10.6	not detected
Choroid plexus	tissue	9.3
Parathyroid gland	tissue	8.7
Endometrium 1	tissue	8.7	not detected
Retina	tissue	7.8
Skeletal muscle	tissue	6.2	not detected
Smooth muscle	tissue	6.2	medium
Thyroid gland	tissue	6.1	medium
Seminal vesicle	tissue	6.0	not detected
Pituitary gland	tissue	5.6
Testis	tissue	5.6	medium
Kidney	tissue	5.6	not detected
Breast	tissue	5.5	medium
Cervix	tissue	5.4	not detected
Prostate	tissue	5.4	not detected
Skin 1	tissue	5.2	not detected
Fallopian tube	tissue	5.1	not detected
Epididymis	tissue	4.8	medium
Tongue	tissue	4.8
Duodenum	tissue	4.8	not detected
Liver	tissue	4.6	not detected
Adrenal gland	tissue	4.6	not detected
Colon	tissue	4.5	not detected
Rectum	tissue	4.4	low
Thymus	tissue	4.3
Small intestine	tissue	4.1	not detected

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Hippocampus, CA1 (35.8), Hippocampus, CA3 (35.0), Ventral hippocampus (34.7), Subiculum (34.0), Dorsal hippocampus (32.8).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting LANCL2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 83 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-3681-5P	99.82	66.88	387
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4307	99.82	70.45	3374

Functional genomics

gnomAD constraint: pLI 7.9e-07, LOEUF 0.846, missense Z 0.185 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000254770 splits into 2 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
7:55,366,026–55,391,832	184 / 111.8	1.65	no
7:55,391,833–55,431,317	378 / 468.4	0.81	no

Literature-anchored findings (GeneRIF, showing 13)

• cDNA cloned and characterized. May play a role as a component of a peptide-modifying complex (PMID:11762191)
• Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. (PMID:12566319)
• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• Data show that lanthionine synthetase C-like protein (LANCL2) is required for abscisic acid binding on human granulocyte membranes and that LANCL2 is necessary for transduction of the ABA signal into granulocytes and rat insulinoma cells. (PMID:19667068)
• Molecular docking studies predict that ABA and other PPAR gamma agonists (e.g., rosiglitazone and pioglitazone) share a binding site on the surface of LANCL2. (PMID:20512604)
• human recombinant LANCL2 binds abscisic acid (ABA) directly and provide the first demonstration of ABA binding to a mammalian ABA receptor. (PMID:22037458)
• Data indicate that lanthionine synthetase C-like 2 (LanCL2) depletion sensitizes cells to apoptosis through down-regulating serine/threonine protein kinase Akt phosphorylation. (PMID:25273559)
• human LANCL2 is a non-transmembrane G protein-coupled receptor susceptible to hormone-induced nuclear translocation. (PMID:27222287)
• Site-directed mutagenesis (single mutant R118I, triple mutants R118I/R22I/K362I and R118I/S41A/E46I) and equilibrium binding experiments on the mutated LANCL2 proteins identified a high-affinity ABA-binding site involving R118, with a KD of 2.6nM+/-1.2nM, as determined by surface plasmon resonance. (PMID:29421190)
• Abscisic acid enriched fig extract promotes insulin sensitivity by decreasing systemic inflammation and activating LANCL2 in skeletal muscle. (PMID:32591558)
• Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. (PMID:33568630)
• Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients. (PMID:34461927)
• Abscisic acid signaling through LANCL2 and PPARgamma induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells. (PMID:38624012)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	lancl2	ENSDARG00000045465
mus_musculus	Lancl2	ENSMUSG00000062190
rattus_norvegicus	Lancl2	ENSRNOG00000006810
drosophila_melanogaster	CG2061	FBGN0027498

Paralogs (2): LANCL1 (ENSG00000115365), LANCL3 (ENSG00000147036)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1919085) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 8 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal heart morphology	1
enlarged heart	1
abnormal coat/hair pigmentation	1
abnormal kidney morphology	1
decreased susceptibility to bacterial infection	1
enlarged kidney	1
decreased macrophage cell number	1
decreased regulatory T cell number	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bos taurus	F1MVX2	90.5%	Diamond
Drosophila pseudoobscura pseudoobscura	Q29HZ1	85.2%	Diamond
Arabidopsis thaliana	F4IEM5	64.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ELDR	ncRNA	102725541
VOPP1	protein-coding	81552
VOPP1-DT	ncRNA	105375287
EGFR-AS1	ncRNA	100507500
EGFR	protein-coding	1956

Protein

Protein identifiers

LanC-like protein 2 — Q9NS86 (reviewed: Q9NS86)

Alternative names: Testis-specific adriamycin sensitivity protein

All UniProt accessions (2): H7BZ40, Q9NS86

UniProt curated annotations — full annotation on UniProt →

Function. Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.

Subunit / interactions. Interacts with an array of inositol phospholipids such as phosphatidylinositol 3-phosphate (PI3P), phosphatidylinositol 4-phosphate (PI4P) and phosphatidylinositol 5-phosphate (PI5P). PIP-binding enhances membrane association.

Subcellular location. Nucleus. Cytoplasm. Cell membrane.

Tissue specificity. Expressed in brain and testis.

Post-translational modifications. Myristoylated. Essential for membrane association.

Miscellaneous. Its exogenous expression in a sarcoma cell line decreases the expression of ABCB1 (P-glycoprotein 1) and increases cellular sensitivity to an anticancer drug (adriamycin).

Similarity. Belongs to the LanC-like protein family.

RefSeq proteins (1): NP_061167* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007822	LANC-like	Family
IPR012341	6hp_glycosidase-like_sf	Homologous_superfamily
IPR020464	LanC-like_prot_euk	Family

Pfam: PF05147

UniProt features (40 total): helix 20, turn 8, strand 4, sequence variant 2, initiator methionine 1, chain 1, region of interest 1, modified residue 1, lipid moiety-binding region 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures by resolution:

PDB	Title	Method	Resolution (Å)
6WQ1	Eukaryotic LanCL2 protein	X-RAY DIFFRACTION	2.29

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NS86-F1	92.37	0.87

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol; nucleoplasm

Antibody reliability (HPA): IH uncertain · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2)

Type	Positions
Phosphotyrosine	198
N-myristoyl glycine	2

Mutagenesis-validated functional residues (1)

Position	Phenotype
2	loss of membrane localization and results in localization to the nucleus, particularly to the nucleoli.

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 201 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, MODULE_255, GOBP_CELLULAR_RESPONSE_TO_LIPID, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MODULE_317, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_PEPTIDE_METABOLIC_PROCESS, MARTINEZ_RB1_TARGETS_UP, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GARY_CD5_TARGETS_DN

GO Biological Process (5): carbohydrate metabolic process (GO:0005975), regulation of abscisic acid-activated signaling pathway (GO:0009787), positive regulation of abscisic acid-activated signaling pathway (GO:0009789), peptide modification (GO:0031179), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (6): ATP binding (GO:0005524), GTP binding (GO:0005525), phosphatidylinositol-5-phosphate binding (GO:0010314), phosphatidylinositol-3-phosphate binding (GO:0032266), phosphatidylinositol-4-phosphate binding (GO:0070273), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), cortical actin cytoskeleton (GO:0030864), cytoplasm (GO:0005737)

GO top-level categories

25 GO namespaces:

Category	Terms
anion binding	4
phosphatidylinositol phosphate binding	3
cellular anatomical structure	3
abscisic acid-activated signaling pathway	2
purine ribonucleoside triphosphate binding	2
primary metabolic process	1
regulation of signal transduction	1
regulation of cellular response to alcohol	1
regulation of abscisic acid-activated signaling pathway	1
positive regulation of signal transduction	1
peptide metabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
adenyl ribonucleotide binding	1
guanyl ribonucleotide binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
actin cytoskeleton	1
cortical cytoskeleton	1
intracellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 10 of 17 annotations. The rest are phylogenetic / computational / electronic (IEA).

10 experimentally-supported GO terms:

GO term	NS	Evidence
negative regulation of DNA-templated transcription	BP	direct assay
positive regulation of abscisic acid-activated signaling pathway	BP	direct assay
cortical actin cytoskeleton	CC	direct assay
cytosol	CC	direct assay
nucleoplasm	CC	direct assay
nucleus	CC	direct assay
plasma membrane	CC	direct assay
phosphatidylinositol-3-phosphate binding	MF	direct assay
phosphatidylinositol-4-phosphate binding	MF	direct assay
phosphatidylinositol-5-phosphate binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 532 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LANCL2	EPS8	Q12929	715
LANCL2	VOPP1	Q96AW1	689
LANCL2	SEC61G	P38384	642
LANCL2	ABCB1	P08183	601
LANCL2	ECD	O95905	548
LANCL2	EGFR	P00533	545
LANCL2	SEPTIN14	Q6ZU15	505
LANCL2	VSTM2A	Q8TAG5	444
LANCL2	C7orf25	Q9BPX7	407
LANCL2	UCP1	P25874	378
LANCL2	SUMF2	Q8NBJ7	370
LANCL2	RB1CC1	Q8TDY2	368
LANCL2	STK17A	Q9UEE5	365
LANCL2	ZNF713	Q8N859	352
LANCL2	INS	P01308	350

IntAct

Human interaction partners of LANCL2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
APPBP2	physical association	0.720	6
SIAH1	physical association	0.560	3
TDRKH	physical association	0.560	3
TERF2IP	physical association	0.510	2
TERF2	physical association	0.370	1
DISC1	physical association	0.000	1

BioGRID (114 interactions; top human partners by supporting records): AKT1 (Affinity Capture-Western; 3 records), FAM188A (Affinity Capture-MS; 3 records), APPBP2 (Two-hybrid; 2 records), CCNF (Affinity Capture-MS; 2 records), DOK2 (Affinity Capture-MS; 2 records), FEZ1 (Affinity Capture-MS; 2 records), GMFG (Affinity Capture-MS; 2 records), GSTM3 (Affinity Capture-MS; 2 records), KCNJ5 (Affinity Capture-MS; 2 records), PARK2 (Affinity Capture-MS; 2 records), PVR (Affinity Capture-MS; 2 records), AAR2 (Affinity Capture-MS), AIRE (Affinity Capture-MS), ANKRD39 (Affinity Capture-MS), ANLN (Affinity Capture-MS)

Disease & clinical

Genetic variants

Variant evidence for LANCL2: 83 ClinVar records (0 pathogenic / likely pathogenic); 5 GWAS associations.

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	3
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 36 predictions of 1,013):

Position(s)	Effect	Δscore	Sites
7:55391783–55391784	acceptor_gain	1.0000	2
7:55391791–55391792	acceptor_loss	1.0000	5
7:55401172–55401173	acceptor_loss	1.0000	5
7:55410025	donor_gain	1.0000
7:55411898	acceptor_gain	1.0000
7:55411904–55411905	acceptor_gain	1.0000	2
7:55411905–55411906	acceptor_loss	1.0000	5
7:55412090–55412091	donor_loss	1.0000	5
7:55425252–55425253	acceptor_loss	1.0000	5
7:55366230–55366231	donor_loss	0.9900	5

AlphaMissense

1,278 missense substitutions predicted likely pathogenic (of 2,903 scored), across 314 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M421	9	0.896	0.984
H264	8	0.999	1.000
H322	8	0.999	1.000
H368	8	0.999	1.000
D412	8	0.997	0.999
D315	8	0.989	0.998
D99	8	0.982	0.996
H319	8	0.972	0.997
H255	8	0.971	0.999
N305	8	0.966	0.999
H406	8	0.963	0.986
F147	8	0.955	0.996
F396	8	0.946	0.997
D96	8	0.933	0.983
F377	8	0.930	0.988
F439	8	0.920	0.984
D151	8	0.896	0.971
D83	8	0.697	0.861
C321	7	0.999	1.000
W254	7	0.998	1.000

HPA cancer prognostics

RNA cancer specificity: Group enriched (Glioblastoma Multiforme, Testicular Germ Cell Tumor)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	2.33e-05
Stomach Adenocarcinoma (TCGA)	unfavorable	5.55e-05
Pancreatic Adenocarcinoma (TCGA)	favorable	0.000112
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000184

Disease associations

OMIM: gene MIM:612919 | disease phenotypes:

GWAS associations

5 associations:

Study	Trait	p-value
GCST004033_17	QRS interval (sulfonylurea treatment interaction)	6e-8
GCST007622_3	Impulsivity	1e-6
GCST002927_19	Mercury levels	3e-6
GCST009306_15	Spatial processing	6e-6
GCST009391_1309	Metabolite levels	8e-6

EFO canonical traits (from GWAS)

4 canonical traits:

EFO ID	Trait name
EFO:0007922	response to sulfonylurea
EFO:0006946	behavioural disinhibition measurement
EFO:0008354	cognitive function measurement
EFO:0010408	triacylglycerol 50:1 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3351212 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 347 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL4788758	OMILANCOR	2	347

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Abscisic acid receptor complex

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
abscisic acid	Binding	7.96	pKd
omilancor	Binding	5.11	pKd

Binding affinities (BindingDB)

96 measured of 96 human assays (96 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL3355910	IC50	6.6 nM
6-(1H-benzimidazol-2-yl)-N-[3-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-3-azabicyclo[3.1.0]hexan-6-yl]pyridine-2-carboxamide	KD	719 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-(1H-benzimidazol-2-yl)-N-[3-[3-[(1,4-dioxonaphthalen-2-yl)amino]-4-methylbenzoyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridine-2-carboxamide	KD	1710 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-(1H-benzimidazol-2-yl)-N-[3-[3-(1,3-benzothiazol-2-yl)benzoyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridine-2-carboxamide	KD	1900 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-[[4-[3-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-3,9-diazaspiro[5.5]undecane-9-carbonyl]benzoyl]amino]thiophene-2-carboxamide	KD	1910 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]-2-(pyridin-2-ylamino)pyrimidine-4-carboxamide	KD	2010 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
2-[5-[3-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-3,9-diazaspiro[5.5]undecane-9-carbonyl]-2-methylanilino]naphthalene-1,4-dione	KD	2090 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]-(2-morpholin-4-ylpyrimidin-4-yl)methanone	KD	2300 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-imidazo[1,2-a]pyridin-2-yl-N-[(1R,5S)-3-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-3-azabicyclo[3.1.0]hexan-6-yl]benzamide	KD	2530 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]-6-(pyridin-2-ylamino)pyridine-2-carboxamide	KD	2830 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]-(3-nitrophenyl)methanone	KD	3210 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]methanone	KD	3440 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-(1H-benzimidazol-2-yl)-N-[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridine-2-carboxamide	KD	3670 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-imidazo[1,2-a]pyridin-2-yl-N-[(1R,5S)-3-(1H-indazole-3-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl]benzamide	KD	4320 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]methanone	KD	4460 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-imidazo[1,2-a]pyridin-2-yl-N-[2-[(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)amino]phenyl]benzamide	KD	4460 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[1-(2-anilinopyrimidine-4-carbonyl)piperidin-4-yl]-2-(pyridin-2-ylamino)pyrimidine-4-carboxamide	KD	5410 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-(1H-benzimidazol-2-yl)-N-[3-[3-(4-methylimidazol-1-yl)benzoyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyridine-2-carboxamide	KD	5840 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
4-butoxy-N-[1-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)piperidin-4-yl]benzamide	KD	6190 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[1-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)pyrrolidin-2-yl]-[2-(4-nitrophenyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]methanone	KD	6330 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
1,3-bis(3-imidazo[1,2-a]pyridin-2-ylphenyl)urea	KD	6780 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]-(3-imidazo[1,2-a]pyridin-2-ylphenyl)methanone	KD	6920 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
(6-anilino-2-pyridinyl)-[3-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-3,9-diazaspiro[5.5]undecan-9-yl]methanone	KD	6930 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-anilino-N-[1-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)piperidin-4-yl]pyridine-2-carboxamide	KD	7040 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[4-(1H-benzimidazol-2-yl)piperidin-1-yl]-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]methanone	KD	8020 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
(6-anilino-2-pyridinyl)-[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]methanone	KD	8310 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[3-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-3,9-diazaspiro[5.5]undecan-9-yl]-(3-imidazo[1,2-a]pyridin-2-ylphenyl)methanone	KD	8730 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-N-(3-imidazo[1,2-a]pyridin-2-ylphenyl)piperazine-1-carboxamide	KD	8730 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[5-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(3-chloro-4-fluorophenyl)methanone	KD	8790 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[1-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperidin-4-yl]-3-nitrobenzamide	KD	9090 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[5-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(4-phenylphenyl)methanone	KD	9380 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[(1R,5S)-3-(6-anilinopyridine-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl]-3-imidazo[1,2-a]pyridin-2-ylbenzamide	KD	9500 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[1-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperidin-4-yl]-2-(pyridin-2-ylamino)pyrimidine-4-carboxamide	KD	9880 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
2-anilino-N-[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]pyrimidine-4-carboxamide	KD	10300 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[6-(1H-benzimidazol-2-yl)-2-pyridinyl]-[5-(quinoline-3-carbonyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]methanone	KD	10300 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-anilino-N-[1-(6-anilinopyridine-2-carbonyl)piperidin-4-yl]pyridine-2-carboxamide	KD	10800 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
(2-anilinopyrimidin-4-yl)-[3-[2-(pyridin-2-ylamino)pyrimidine-4-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]methanone	KD	12200 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-imidazo[1,2-a]pyridin-2-yl-N-[(1S,5R)-3-(3-pyrrol-1-ylthiophene-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl]benzamide	KD	12500 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
2-anilino-N-[1-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)piperidin-4-yl]pyrimidine-4-carboxamide	KD	13200 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
(2-anilinopyrimidin-4-yl)-[3-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-3,9-diazaspiro[5.5]undecan-9-yl]methanone	KD	13300 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
6-anilino-N-[1-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperidin-4-yl]pyridine-2-carboxamide	KD	13300 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
2-[5-[4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazine-1-carbonyl]-2-methylanilino]naphthalene-1,4-dione	KD	14800 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[2-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-2,8-diazaspiro[4.5]decan-8-yl]-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]methanone	KD	14900 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
(6-anilino-2-pyridinyl)-[5-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]methanone	KD	16400 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-imidazo[1,2-a]pyridin-2-yl-N-[1-(3-imidazo[1,2-a]pyridin-2-ylbenzoyl)piperidin-4-yl]benzamide	KD	16400 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[5-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(3-imidazo[1,2-a]pyridin-2-ylphenyl)methanone	KD	16800 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
N-[1-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperidin-4-yl]-3-imidazo[1,2-a]pyridin-2-ylbenzamide	KD	17000 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-imidazo[1,2-a]pyridin-2-yl-N-[(1S,5R)-3-(2-phenoxypyridine-3-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl]benzamide	KD	17500 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
3-[[4-[4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazine-1-carbonyl]benzoyl]amino]thiophene-2-carboxamide	KD	17700 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
[6-(1H-benzimidazol-2-yl)-2-pyridinyl]-[5-(4-methylpyridine-3-carbonyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]methanone	KD	18300 nM	US-20240101552: CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.18	IC50	6.56	nM	CHEMBL3355910
5.11	Kd	7700	nM	OMILANCOR

PubChem BioAssay actives

2 with measured affinity, of 19 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2Z,4E)-5-(2-hydroxy-1,3,3-trimethyl-5-oxo-7-oxabicyclo[4.1.0]heptan-2-yl)-3-methylpenta-2,4-dienoic acid	1176049: Inhibition of ABA binding to LANCL2 (unknown origin)	ic50	0.0066	uM
[4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]methanone	1714416: Binding affinity to LANCL2 (unknown origin) by surface plasmon resonance analysis	kd	7.7000	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	5
Cisplatin	affects expression, affects cotreatment, decreases expression	3
bisphenol A	decreases expression, increases expression	2
trichostatin A	affects expression, decreases expression	2
Smoke	decreases expression, increases abundance	2
GSK-J4	decreases expression	1
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
sodium arsenite	increases expression	1
tetrabromobisphenol A	decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Decitabine	affects expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Mercury	decreases expression	1
Methotrexate	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3374271	Binding	Inhibition of ABA binding to LANCL2 (unknown origin)	Synthesis, structural characterization and effect on human granulocyte intracellular cAMP levels of abscisic acid analogs. — *Bioorg Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for LANCL2 across ~30M SureChEMBL compounds — explore on Sugi Predict.